This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
User:Estelle Metzger/Sandbox
From Proteopedia
(Difference between revisions)
| Line 5: | Line 5: | ||
Thanks to the similarity between LRRK2 and Roco4 from the ''Dictyostelium'', Roco4 is used in studies with a view to finding that inhibitor. One of the candidates to inhibit this activity is LRRK2-IN-1<ref name="Bernd">doi: 10.1021/jm5018779</ref>. | Thanks to the similarity between LRRK2 and Roco4 from the ''Dictyostelium'', Roco4 is used in studies with a view to finding that inhibitor. One of the candidates to inhibit this activity is LRRK2-IN-1<ref name="Bernd">doi: 10.1021/jm5018779</ref>. | ||
| - | Pour ajouter une référence : <ref>Rentrer doi:... de la publi</ref> et si on veut utiliser la réf plusieurs fois, il faut lui donner un nom | ||
== Humanized Roco4 == | == Humanized Roco4 == | ||
| Line 28: | Line 27: | ||
== LRRK2-IN-1 == | == LRRK2-IN-1 == | ||
| - | + | [[Image:4K4-270.png|thumb|LRRK2-IN-1 structure]] | |
| - | <scene name='75/751216/Lrrk2-in-1/1'>LRRK2-IN-1</scene> is a type 1 inhibitor. It is the first identified LRRK2-specific inhibitor, which is now a common tool compound for the LRRK2 research community. LRRK2-IN-1 has a 2-amino-5,11- dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepine-6(11H)-one scaffold. | + | <scene name='75/751216/Lrrk2-in-1/1'>LRRK2-IN-1</scene> is a type 1 inhibitor. It is the first identified LRRK2-specific inhibitor, which is now a common tool compound for the LRRK2 research community. LRRK2-IN-1 has a 2-amino-5,11- dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepine-6(11H)-one scaffold. |
The function is of LRRK2-In-1 is to dephosphorylate LRRK2 residues Ser910 and Ser935 in the kidney, but not in the brain. This compound is not capable of crossing the blood-brain barrier. | The function is of LRRK2-In-1 is to dephosphorylate LRRK2 residues Ser910 and Ser935 in the kidney, but not in the brain. This compound is not capable of crossing the blood-brain barrier. | ||
The structure of LRRK2-In-1 does not stabilize the active conformation. Indeed, the activation loop is poorly resolved indicating that it is flexible. Moreover, it presents a closure of the glycine-rich loop in the inhibitor structure <ref name="Bernd"/>. | The structure of LRRK2-In-1 does not stabilize the active conformation. Indeed, the activation loop is poorly resolved indicating that it is flexible. Moreover, it presents a closure of the glycine-rich loop in the inhibitor structure <ref name="Bernd"/>. | ||
Revision as of 15:14, 26 January 2017
Humanized Roco4 bound to LRRK2-IN-1
| |||||||||||
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Gilsbach BK, Messias AC, Ito G, Sattler M, Alessi DR, Wittinghofer A, Kortholt A. Structural Characterization of LRRK2 Inhibitors. J Med Chem. 2015 May 1. PMID:25897865 doi:http://dx.doi.org/10.1021/jm5018779
- ↑ Gilsbach BK, Kortholt A. Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation. Front Mol Neurosci. 2014 May 5;7:32. doi: 10.3389/fnmol.2014.00032. eCollection, 2014. PMID:24847205 doi:http://dx.doi.org/10.3389/fnmol.2014.00032
